© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 497-504,
April 3, 2002
© 2002 Oxford University Press
ARTICLE |
Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women
Affiliation of authors: T. Riman, Department of Obstetrics and Gynecology, Falu Hospital, Falun, Sweden, Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden, and Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; P. W. Dickman, N. Correia, C. M. Magnusson, I. R. Persson, Department of Medical Epidemiology, Karolinska Institute; S. Nilsson, Department of Obstetrics and Gynecology, Falu Hospital, and Department of Women's and Children's Health, Uppsala University; H. Nordlinder, Department of Pathology, Uppsala University, and Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden; E. Weiderpass, Department of Medical Epidemiology, Karolinska Institute, Stockholm, and International Agency for Research on Cancer, Lyon, France.
Correspondence to: Tomas Riman, M.D., Department of Obstetrics and Gynecology, Falu Hospital, 79182 Falun, Sweden (e-mail: tomas.riman{at}ltdalarna.se).
Background: Estrogen replacement therapy (ERT), which is mainly used to relieve climacteric symptoms, increases a woman's risk for uterine endometrial cancer and epithelial ovarian cancer (EOC). Estrogens are often combined with progestins in hormone replacement therapy (HRT) to reduce the risk of uterine endometrial cancer. Data on the association between HRT including progestins and EOC risk are limited. This nationwide case–control study examined EOC risk in relation to HRT regimens with sequentially added progestins (HRTsp) and continuously added progestins (HRTcp). Methods: Between 1993 and 1995, we enrolled 655 histologically verified incident case patients with EOC and 3899 randomly selected population controls, all 50–74 years of age. Data on HRT use were collected through mailed questionnaires. Multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by the use of unconditional logistic regression. Results: Risks of EOC were elevated among ever users as compared with never users of both ERT (OR = 1.43, 95% CI = 1.02 to 2.00) and HRTsp (OR = 1.54, 95% CI = 1.15 to 2.05); risks were elevated for serous, mucinous, and endometrioid subtypes. For all EOC types combined, the greatest risk increases were seen with hormone use exceeding 10 years. Ever use of HRTcp was not associated with increased EOC risk relative to HRTcp never use (OR = 1.02, 95% CI = 0.73 to 1.43). The risk of EOC was elevated among HRTsp ever users as compared with HRTcp ever users (OR = 1.78, 95% CI = 1.05 to 3.01). ORs for EOC after ever use of low-potency estrogens were 1.18 (95% CI = 0.89 to 1.55) for oral and 1.33 (95% CI = 1.03 to 1.72) for vaginal applications, but no relationship was seen between EOC risk and duration of use. Conclusion: Ever users of ERT and HRTsp but not HRTcp may be at increased risk of EOC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Gates, B. A. Rosner, J. L. Hecht, and S. S. Tworoger Risk Factors for Epithelial Ovarian Cancer by Histologic Subtype Am. J. Epidemiol., November 12, 2009; (2009) kwp314v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Morch, E. Lokkegaard, A. H. Andreasen, S. Kruger-Kjaer, and O. Lidegaard Hormone Therapy and Ovarian Cancer JAMA, July 15, 2009; 302(3): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tian, Z. Wu, Y. Zhao, Y. Meng, Y. Si, X. Fu, Y. Mu, and W. Han Differential induction of LRP16 by liganded and unliganded estrogen receptor {alpha} in SKOV3 ovarian carcinoma cells J. Endocrinol., July 1, 2009; 202(1): 167 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T Goodman, G. Lurie, P. J Thompson, K. E McDuffie, and M. E Carney Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk Endocr. Relat. Cancer, December 1, 2008; 15(4): 1055 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Corrao, A. Zambon, V. Conti, F. Nicotra, C. La Vecchia, C. Fornari, G. Cesana, P. Contiero, G. Tagliabue, R. E. Nappi, et al. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation Ann. Onc., January 1, 2008; 19(1): 150 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rossing, K. L. Cushing-Haugen, K. G. Wicklund, J. A. Doherty, and N. S. Weiss Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2548 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Beesley, S. J. Jordan, A. B. Spurdle, H. Song, S. J. Ramus, S. K. Kjaer, E. Hogdall, R. A. DiCioccio, V. McGuire, A. S. Whittemore, et al. Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2557 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, P. W. Dickman, M. Lambe, H.-O. Adami, D. Trichopoulos, T. Riman, C.-c. Hsieh, and S. Cnattingius Gestational Age and Fetal Growth in Relation to Maternal Ovarian Cancer Risk in a Swedish Cohort Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1828 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Soegaard, A. Jensen, E. Hogdall, L. Christensen, C. Hogdall, J. Blaakaer, and S. K. Kjaer Different Risk Factor Profiles for Mucinous and Nonmucinous Ovarian Cancer: Results from the Danish MALOVA Study Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1160 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Choi, A. S. T. Wong, H.-F. Huang, and P. C. K. Leung Gonadotropins and Ovarian Cancer Endocr. Rev., June 1, 2007; 28(4): 440 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Albanito, A. Madeo, R. Lappano, A. Vivacqua, V. Rago, A. Carpino, T. I. Oprea, E. R. Prossnitz, A. M. Musti, S. Ando, et al. G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells Cancer Res., February 15, 2007; 67(4): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Lacey Jr., L. A. Brinton, M. F. Leitzmann, T. Mouw, A. Hollenbeck, A. Schatzkin, and P. Hartge Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst, October 4, 2006; 98(19): 1397 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Lin, Y.-L. Tsai, M.-T. Huang, Y.-P. Lu, C.-T. Ho, S.-F. Tseng, and S.-C. Teng Inhibition of estradiol-induced mammary proliferation by dibenzoylmethane through the E2-ER-ERE-dependent pathway Carcinogenesis, January 1, 2006; 27(1): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lukanova and R. Kaaks Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 98 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Glud, S. K. Kjaer, B. L. Thomsen, C. Hogdall, L. Christensen, E. Hogdall, J. E. Bock, and J. Blaakaer Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer Arch Intern Med, November 8, 2004; 164(20): 2253 - 2259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Wathen, D. S. Feig, J. W. Feightner, B. L. Abramson, and A. M. Cheung Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care Can. Med. Assoc. J., May 11, 2004; 170(10): 1535 - 1537. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Labrie, M. El-Alfy, L. Berger, C. Labrie, C. Martel, A. Belanger, B. Candas, and G. Pelletier The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women's Health? Endocrinology, November 1, 2003; 144(11): 4700 - 4706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Anderson, H. L. Judd, A. M. Kaunitz, D. H. Barad, S. A. A. Beresford, M. Pettinger, J. Liu, S. G. McNeeley, and A. M. Lopez Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures: The Women's Health Initiative Randomized Trial JAMA, October 1, 2003; 290(13): 1739 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hall and K. S. Korach Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells Mol. Endocrinol., May 1, 2003; 17(5): 792 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Burry, J. M. Cain, L. Gilbert, S. Krishnamurthy, S. L. Tan, E. L. Franco, J. V. Lacey, Jr, P. J. Mink, J. H. Lubin, M. E. Sherman, et al. Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women JAMA, November 27, 2002; 288(20): 2538 - 2539. [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Shanafelt, D. L. Barton, A. A. Adjei, and C. L. Loprinzi Pathophysiology and Treatment of Hot Flashes Mayo Clin. Proc., November 1, 2002; 77(11): 1207 - 1218. [Abstract] [PDF]
|
|
|
|
|
|
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan Postmenopausal Hormone Replacement Therapy: Scientific Review JAMA, August 21, 2002; 288(7): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson Assessing Benefits and Harms of Hormone Replacement Therapy: Clinical Applications JAMA, August 21, 2002; 288(7): 882 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, and I. R. Persson Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case-Control Study Am. J. Epidemiol., August 15, 2002; 156(4): 363 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition J. Clin. Oncol., August 1, 2002; 20(15): 3328 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Lacey Jr, P. J. Mink, J. H. Lubin, M. E. Sherman, R. Troisi, P. Hartge, A. Schatzkin, and C. Schairer Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer JAMA, July 17, 2002; 288(3): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Noller Estrogen Replacement Therapy and Risk of Ovarian Cancer JAMA, July 17, 2002; 288(3): 368 - 369. [Full Text] [PDF]
|
|